NEURIZON THERAPEUTICS LIMITED (NUZ)
Share Price Analysis and Chart

18/03/2025

1

Speculative Buy

$0.42

211.11%

Morgans observes Neurizon Therapeutics is expected to start two animal studies, which will take four weeks to finish and are aimed at addressing the questions posed by the DFA on NUZ-001 regarding systemic exposure, the analyst explains.

The start of trials is delayed by around six months and falls within the latter part of the 12-month delay the broker had originally factored in for unexpected delays.

Morgans makes no change to earnings forecasts, and the analyst believes the company retains a strong strategic role in the rare disease segment.

The Speculative Buy rating and 42c target price are retained.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.

06/05/2025

1

Buy

$0.45

233.33%

Neurizon Therapeutics announced the last patient in its amyotrophic lateral sclerosis (ALS) open-label extension (OLE) study has completed 12 months of treatment with NUZ-001. This keeps top-line results on track for release in Q3 of 2025 notes Petra Capital.

Updated interim data continue to show compelling survival benefits, with NUZ-001 reducing the risk of death by -78.5% versus matched historical controls, highlights the analyst.

NUZ-001 offers offering a potential survival benefit of circa 11 months, well above the 3-6 month benefit of current ALS therapies, explains the broker. The drug remains safe and well-tolerated, with some patients now on treatment for over 30 months.

Petra Capital remains confident in NUZ-001’s potential, highlighting the superior survival trend and ongoing durability of response.

Target price of 45c and Buy rating are unchanged.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.00 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.20 cents.